Among melanoma patients that received chemotherapy, circulating DNA of mutant BRAF was associated with a significantly worse overall survival compared to wild-type-BRAF patients, corresponding to 13 months and 30.6 months, respectively [24]. The gene discussed is BRAF; the disease is melanoma.